IN THE UNITED STATES PATENT OFFICE

Application Serial No. (To be assigned)

Our Ref.

P-1459(O)

Entry into National Phase from PCT/CA97/00172

Applicants:

Hyal Pharmaceutical Corporation

NOV 1 3 2000

Attorney

7

Ivor M. Hughes

Suite 200

175 Commerce Valley Drive West Thornhill, Ontario

L3T 7P6

Title:

METHODS FOR CELL MOBILIZATION

USING IN VIVO TREATMENT WITH

HYALURONAN

COPY

Inventor:

Linda May Pilarski

September 10, 1998

The Commissioner of Patents UNITED STATES PATENT OFFICE 2011 South Clark Place Crystal Plaza 2, Room 1B03 Arlington, Virginia 22202 U.S.A.

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants and the undersigned are aware of "patents, publication, or other information" which they believe may be material to the examination of the above-identified application. One sheet of Form PTO-1449 listing them, is submitted herewith pursuant to 37 C.F.R. §§ 1.97-1.99 and to the duty of disclosure set forth in 37. C.F.R. § 1.56.

Although this Information Disclosure Statement identifies references which may be "material," it is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" (within the meaning of 35 U.S.C. § 102 103) as to the invention disclosed and claimed in this application unless specifically designated as such. Moreover, no representation is intended as to the relative relevance of any portion of the



references or relevance among references, whether cited in this Statement or elsewhere.

In accordance with 37 C.F.R. § 1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a novelty search has been made or that no other information which may be material (as defined in 37. C.F.R. § 1.56(a)) exists.

U.S. PATENT DOCUMENTS

Document Number	Date	IVante
4,725,585	February 16, 1988	Wenge Per S.W., et al
4,141,973	February 27, 1979	Balazs, Endre A.

FOREIGN PATENT DOCUMENTS

arrana and Marinahan

Document Number	<u>Date</u>	Name
<u>Canada</u>		
1,205,031	May 27, 1986	Lorenzi, S., et al
PCT Application		·
WO96/05845 WO91/04058	February 29, 1996 April 4, 1991	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Gowland G., et al Marked Enhanced Efficacy of Cyclosporin When Combined With Hyaluronic Acid Evidence From Two T Cell-Mediated Models. Clinical Drug Investigation, Vol. 11, No. 4, 1996, Pages 245-250, XPOOO613356

Toole, B.P. Hyaluronan and its binding proteins, the hyaladherins. Curr. Opin. Cell. Biol. 2: 839-844 (1990)

Toole, B.P. **Development role of hyaluronate.** *Conn. Tiss. Res.* 10: 93-100 (1982)

Page 3

Entwistle, J. Zhang, S., Yang, B., Wong, C. Hall, C.L., Curpen, G., Mowat M., Greenberg, A.H., and Turley, E.A.

Cloning and characterization of the gene encoding the hyaluronan receptor RHAMM; the role of a secreted isoform in the regulation of focal adhesion formation.

Gene 163: 233-238 (1995)

'n

Yang, B., Yang, X. Zhang, S., Turley, M., Samuel, S., Savani, R.C., Greenberg, A.H., and Turley, E.A.

Overexpression of the hyaluronan receptor RHAMM is transforming, and is

required for H-ras transformation.

Cell 82: 19-28 (1995)

Masellis-Smith, A., Belch, A.R., Mant, M.J., Turley, E.A., and Pilarski., L.M. Hyaluronan-dependent motility of B cells and leukemic plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44.

Blood 87: 1891-1899 (1996)

Turley, E.A., Belch, A.R., Poppema, S., and Pilarski, L.M. Expression and function of a receptor for hyaluronan-mediated motility (RHAMM) on normal and malignant B lymphocytes. Blood 81: 446-453 (1993)

Pilarski, L.M., Miszta, H., and Turley, E.A. Regulation expression of a receptor for hyaluronan-mediated motility RHAMM on human thymocytes and T cells J. Immunol. 150: 4292-4302 (1993)

S. K.B., McCoshen, J., Kredentser, J., and Turley, E. The Regulation of Sperm Motlity by a Novel Hyaluronan Receptor. Fertility and Sterility 61: 935-940 (1994)

Turely, E.A., Sossain, M.Z., Sorokan, T., Jordan, L.M. and Nagy, J.I. Astrocyte and microglial motility in vitro is functionally dependent on the hyaluronan receptor RHAMM Glia 12: 68-80 (1994)

Golub, E.S., Green, D.R. Immunology A Synthesis 2:205, (1991)

Kuby, J. Immunology 3:50; (1997)

Roitt, I., Brostoff, J., Male, D. Immunology 4:2.1

Page 4

Weaver, C.H., Hazeltonn, B., Birch, R., Palmer, P., Allen, A., Schwwartzberg, L. and West, W.

An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy Blood 86: 3961-3969 (1995)

Boiron, J.M., Marit, G., Faberes, C., Cony-Makhoul, P., Foures, C., Ferrer, A.M., Cristol, G., Sarrat, A., Girault, D., and Reiffers, J. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human

granulocyte-macrophage colony-stimulating factor (rh GM-CSF). Bone Marrow Transplantation 12: 49-55 (1993)

Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., Wu, S.H., Cao, J., Lee, J.C., Hong, C.H. Lichtenstein, A., Lill, M., Hall, J., Berenson, R., and Berenson, J.

Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.

Blood 86: 390-397 (1995)

If the Examiner wishes to discuss this matter with Applicant's agent, he/she is respectfully requested to contact Ivor M. Hughes or Samuel T. Tekie at (905) 771-6414 collect at her convenience.

Respectfully submitted,

HUGHES, ETIGSON

lvor M. Hughes

Registration No. 27,759

Agent for Applicant

IMH/mse Enclosures